By Kyle Morris

 

AstraZeneca PLC said Friday that it has signed an exclusive global collaboration and license agreement with Neurimmune for the development and commercialization of NI006, a treatment for transthyretin amyloid cardiomyopathy.

The pharmaceutical giant said its rare disease group Alexion will pay Neurimmune an upfront payment of $30 million, with the potential for additional milestone payments of up to $730 million based on development, regulatory and commercial milestones. In addition, further low-to-mid teen royalties will be paid on net sales of any approved medicine resulting from the agreement.

Under the deal, Alexion will be granted an exclusive worldwide license to develop, manufacture and commercialize NI006.

NI006 is designed to treat transthyretin amyloid cardiomyopathy by enabling the removal of amyloid fibril deposits in the heart, with the potential to treat patients with advanced stages of the condition.

 

Write to Kyle Morris at kyle.morris@dowjones.com

 

(END) Dow Jones Newswires

January 07, 2022 02:29 ET (07:29 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Abr 2022 até Mai 2022 Click aqui para mais gráficos Astrazeneca.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Mai 2021 até Mai 2022 Click aqui para mais gráficos Astrazeneca.